[HTML][HTML] Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label …
…, KC Lung, EYK Tso, R Liu, TWH Chung, MY Chu… - The Lancet, 2020 - thelancet.com
Background Effective antiviral therapy is important for tackling the coronavirus disease 2019
(COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, …
(COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, …
Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients
…, BHS Lam, VWM Chuang, AWH Chu… - Clinical Infectious …, 2022 - academic.oup.com
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron
variant, designated as a variant of concern by the World Health Organization, carries …
variant, designated as a variant of concern by the World Health Organization, carries …
[HTML][HTML] Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations …
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported
from China in January, 2020. SARS-CoV-2 is efficiently transmitted from person to person …
from China in January, 2020. SARS-CoV-2 is efficiently transmitted from person to person …
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
…, C Zhang, JD Ip, WM Chan, AWH Chu… - Emerging microbes & …, 2022 - Taylor & Francis
The novel SARS-CoV-2 Omicron variant (B.1.1.529), first found in early November 2021, has
sparked considerable global concern and it has >50 mutations, many of which are known …
sparked considerable global concern and it has >50 mutations, many of which are known …
Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome …
Background Waning immunity occurs in patients who have recovered from Coronavirus
Disease 2019 (COVID-19). However, it remains unclear whether true re-infection occurs. …
Disease 2019 (COVID-19). However, it remains unclear whether true re-infection occurs. …
Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters
The in vivo pathogenicity, transmissibility, and fitness of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant are not well understood. We …
coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant are not well understood. We …
[HTML][HTML] Emerging SARS-CoV-2 variants expand species tropism to murines
Background Wildtype mice are not susceptible to SARS-CoV-2 infection. Emerging SARS-CoV-2
variants, including B.1.1.7, B.1.351, P.1, and P.3, contain mutations in spike that has …
variants, including B.1.1.7, B.1.351, P.1, and P.3, contain mutations in spike that has …
Rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA. 2 in a single-source community outbreak
VCC Cheng, JD Ip, AWH Chu, AR Tam… - Clinical Infectious …, 2022 - academic.oup.com
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant BA.2 sublineage has increased rapidly in Europe and Asia since January 2022. Here, …
variant BA.2 sublineage has increased rapidly in Europe and Asia since January 2022. Here, …
[HTML][HTML] Transmission of Omicron (B. 1.1. 529)-SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of …
…, LLH Yuen, X Li, DC Lung, AWH Chu… - The Lancet Regional …, 2022 - thelancet.com
With the global evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the causative agent of coronavirus disease 2019 (COVID-19), for almost 2 years, various …
the causative agent of coronavirus disease 2019 (COVID-19), for almost 2 years, various …
[HTML][HTML] Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
JD Ip, AWH Chu, WM Chan, RCY Leung… - …, 2023 - thelancet.com
Background Nirmatrelvir-ritonavir (Paxlovid) and ensitrelvir are 3-chymotrypsin-like cysteine
protease (3CL pro ) inhibitors which have been approved for the treatment of COVID-19 in …
protease (3CL pro ) inhibitors which have been approved for the treatment of COVID-19 in …